

## Leishmaniasis

# SYRIAN ARAB REPUBLIC

# 2014

Published in July 2016 Updated in September 2016

<b>Country General</b>	Information	(WHO,	2013)


Total population:	21,898,000	Age group <15/>14 years, %:	35% / 65%
Gender ratio (%, F/M):	49.1% / 50.9%	Life expectancy at birth in years (F/M):	78 / 73
GDP (PPP int \$)	No data	Number of 1st sub-national administrative level	14. Governorate
Income status:	Lower middle	divisions, name:	14, Governorate

### Epidemiology


	VL	ACL <sup>a</sup>	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	36	53876	No data	0
Number of relapse cases:	No data	1328	No data	0
Total number of cases:	36	55204	No data	0
Imported cases (n, %):	No data	No data	No data	N/A
Gender distribution (% F):	No data	54%	No data	N/A
Age group distribution (%, <5/5-14/>14):	No data	(23/31/46)	No data	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.02	22.74	No data	N/A
Endemic 1st sub-national administrative level divisions for VL or CL (n):	7	14	No data	N/A
Population at risk <sup>1</sup> (%, n/total):	67% (14582000/ 21898000)	108% (23695000/ 21898000)	No data	N/A
Was there any outbreak?	No data	No data	No data	N/A
Number of new <sup>2</sup> foci:	No data	No data	No data	N/A
N/A = not applicable VL = visceral leishmaniasis ACL = anthrop	oonotic cutaneous leishmaniasis	ZCL = zoonotic cutaneous leishmanias	sis MCL = mucocutane	ous leishmaniasis

#### Monthly distribution of new cases January-December


2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	ОСТ	NOV	DEC
VL	3	1	7	2	3	5	4	3	1	1	1	5
CL	5493	5423	6335	5699	3892	3400	2317	2309	2492	3013	5441	8062




Number of new (primary) VL cases reported by



Indicence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014





<sup>1</sup> Defined as "Number of people living in 1st sub-national administrative level endemic areas".

\* No data available

VL cases

Incidence rate (/10 000)

Numerator is based on population data at governorate level from civil affairs records in 2010 while denominator is based on national estimates published in WHO country profiles for 2013.


<sup>2</sup> For this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever


<sup>a</sup> In the Syrian Arab Republic, both ACL and ZCL are endemic but information is only available as aggregated on "cutaneous leishmaniasis"



### Distribution of new CL (left) and new (primary) VL (right) cases

Incidence of cutaneous leishmaniasis in the Syrian Arab Republic in 2014 at governorate level, per 10 000 population





The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boun daries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map production: WHO/HTM/NTD/IDM

### Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	Not available	Year latest national guidelines were published:	2010
Type of surveillance:	Integrated	Is leishmaniasis a notifiable disease (mandatory reporting)?	Yes
Is there a vector control programme?	Yes	Is there a reservoir host control programme?	Yes
Type of insecticide used for IRS:	Pyrethroid, WP and SC	Number of leishmaniasis health facilities:	220

#### Diagnosis

		VL	ACL	ZCL	MCL	
Number of people screened actively for:	Number of people screened actively for:		No data	No data	No data	
Number of people screened passively for:		No data	No data	No data	No data	
VL cases diagnosed by RDT* (%, # RDT+/total VL cases):			N/A	N/A	N/A	
Proportion of positive RDT* (%, # RDT+/total RDT):			N/A	N/A	N/A	
Cases diagnosed by direct exam parasitology) (%, # slides +/total cases):		No data	No data	No data	N/A	
Proportion of positive slides %, # slides +/total slides):		No data	No data	No data	N/A	
Cases diagnosed clinically (%, # clinical cases/total cases):		No data	17% (9223/55204)	No data	N/A	
Percentage of cases with HIV-VL coinfection:		No data	N/A	N/A	N/A	
* These indicators apply only for new (primary) VL cases	VL = visceral I	eishmaniasis	ACL = anthroponotic cutaneous leishm	aniasis ZCL = zoonotic cuta	aneous leishmaniasis	
N/A = not applicable	RDT = rapid d	agnostic test	HIV = human immunodeficiency virus	MCL = mucocutane	MCL = mucocutaneous leishmaniasis	

#### Treatment and medicines

I

Is treatment provided free of charge in the public sector?	Yes
Antileishmanial medicines included in the national List of Essential Medicines:	Sodium stibog

Sodium stibogluconate (SSG), meglumine antimoniate

TREATMENT OUTCOME	VL	
Proportion of relapse cases: <sup>4</sup>	No data	
Initial cure rate:	No data	
Failure <sup>5</sup> rate:	No data	
Case-fatality rate:	No data	

<sup>4</sup> A relapse case in this country is defined as: <sup>5</sup> A failure case in this country is defined as:

d as: No definition available

No definition available

Data source: Ministry of Health, Syrian Arab Republic © WHO 2014. All rights reserved.

Incidence of visceral leishmaniasis in the Syrian Arab Republic in 2014 at governorate level, per 10 000 population